Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
CytoSorbents Corporation (NASDAQ: CTSO) develops life-saving blood purification technologies for critical care and cardiac surgery patients. This dedicated news hub provides investors and medical professionals with essential updates about the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access timely information on earnings reports, product launch announcements, and partnership developments related to CytoSorb® and other polymer adsorption therapies. Our curated collection includes press releases about clinical trial outcomes, European Union regulatory updates, and innovations in cytokine storm management.
Bookmark this page to monitor CTSO’s progress in advancing critical care solutions while staying informed about financial performance and market positioning. Check regularly for verified updates directly from corporate communications and trusted financial news sources.
CytoSorbents announced a virtual Key Opinion Leader and Analyst-Investor Day to discuss the STAR-T pivotal trial results and real-world experience with antithrombotic drug removal in Europe. The event will focus on severe perioperative bleeding in heart surgery patients on blood thinners, including Brilinta®. Experts will present key findings from the STAR-T trial and real-world data in the pre-specified CABG population, addressing the challenges of coronary artery disease and heart attacks globally.
FAQ
What is the current stock price of Cytosorbents (CTSO)?
What is the market cap of Cytosorbents (CTSO)?
